Humacyte (NASDAQ:HUMA) Releases Earnings Results

Humacyte (NASDAQ:HUMA) released its earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05), FiscalAI reports. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 3,047.12%. The business had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.04 million.

Here are the key takeaways from Humacyte’s conference call:

• V012 Phase III interim results exceeded expectations in female dialysis patients: ATEV recipients had 91 more catheter-free days than AV fistula patients, with significantly fewer infections. Humacyte plans to file a supplemental BLA in November 2026 and is targeting a potential launch in late Q2 2027 if priority review is granted.
• Humacyte is rebuilding its SYMVESS commercial organization with vascular-surgery-focused sales personnel, a national accounts strategy, streamlined hospital value-analysis processes, and introductory pricing. At least 20 major U.S. healthcare systems are reportedly in the process of adopting the product, although meaningful benefits are expected mainly in the second half of 2026.
• The FDA accepted Humacyte’s IND for its smaller-diameter CTEV vessel in coronary artery bypass grafting, and the company expects to begin a 10-patient Phase IIa study during the current quarter. Management said initial CTEV manufacturing will not materially constrain ATEV commercial production.
• Financial results continued to reflect commercialization and manufacturing costs: second-quarter revenue was only $0.4 million, cost of goods sold reached $1.2 million including a $0.7 million inventory reserve, and net loss was $36.8 million. Cash, cash equivalents, and restricted cash totaled $80.3 million at June 30, 2026, supported in part by equity-sale proceeds.

Humacyte Stock Performance

Shares of HUMA stock opened at $0.55 on Friday. The company has a debt-to-equity ratio of 5.46, a current ratio of 3.93 and a quick ratio of 3.32. The company has a market cap of $122.11 million, a P/E ratio of -1.12 and a beta of 2.53. Humacyte has a one year low of $0.55 and a one year high of $2.55. The firm has a 50-day moving average of $0.79 and a 200-day moving average of $0.90.

Insider Activity at Humacyte

In other Humacyte news, CFO Dale A. Sander sold 45,887 shares of Humacyte stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the sale, the chief financial officer owned 267,213 shares of the company’s stock, valued at approximately $240,491.70. The trade was a 14.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shamik J. Parikh sold 45,887 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the transaction, the insider owned 272,713 shares in the company, valued at approximately $245,441.70. The trade was a 14.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humacyte

Several institutional investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. purchased a new stake in shares of Humacyte during the 2nd quarter valued at approximately $28,000. Price T Rowe Associates Inc. MD grew its stake in Humacyte by 21.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock valued at $73,000 after buying an additional 13,175 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Humacyte by 41.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company’s stock valued at $96,000 after acquiring an additional 13,407 shares during the period. Financial Advisors Network Inc. bought a new stake in Humacyte during the 2nd quarter valued at $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Humacyte by 25.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,975 shares of the company’s stock worth $161,000 after acquiring an additional 15,649 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HUMA has been the topic of several recent research reports. BTIG Research reissued a “buy” rating and set a $2.00 price objective on shares of Humacyte in a report on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, July 8th. TD Cowen cut their target price on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a research note on Wednesday, June 17th. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Tuesday, April 28th. Finally, Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.11.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.